Praxis (Drug Discovery) Overview
- Year Founded
-
2015
- Status
-
Public
- Employees
-
82
- Stock Symbol
-
PRAX
- Share Price
-
$90.77
- (As of Friday Closing)
Praxis (Drug Discovery) General Information
Description
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The firm's pipeline covers PRAX-114, for the treatment of a broad range of patients suffering from major depressive disorder and post-traumatic stress disorder; PRAX-944, for the treatment of Essential Tremor and Parkinson's Disease; PRAX-562, and PRAX-222, among others.
Contact Information
Website
www.praxismedicines.comCorporate Office
- 99 High Street
- 30th Floor
- Boston, MA 02110
- United States
Corporate Office
- 99 High Street
- 30th Floor
- Boston, MA 02110
- United States
Praxis (Drug Discovery) Stock Performance
As of 14-Feb-2025, Praxis (Drug Discovery)’s stock price is $90.77. Its current market cap is $1.69B with 18.6M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $90.77 | $86.66 | $33.01 - $91.83 | $1.69B | 18.6M | 363K | -$9.17 |
Praxis (Drug Discovery) Financials Summary
As of 30-Sep-2024, Praxis (Drug Discovery) has a trailing 12-month revenue of $1.6M.
|
In Thousands, USD |
TTM 30-Sep-2024 | FY 2023 31-Dec-2023 | FY 2022 31-Dec-2022 | FY 2021 31-Dec-2021 |
|---|---|---|---|---|
| EV | 671,809 | 92,611 | (7,865) | 573,702 |
| Revenue | 1,605 | 2,447 | 0 | 0 |
| EBITDA | (150,596) | (122,845) | (213,610) | (166,879) |
| Net Income | (151,018) | (123,277) | (214,029) | (167,061) |
| Total Assets | 416,256 | 87,948 | 115,128 | 292,747 |
| Total Debt | 1,660 | 2,495 | 3,500 | 4,311 |
Praxis (Drug Discovery) Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Praxis (Drug Discovery) Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price |
% Owned |
|---|
Praxis (Drug Discovery) Comparisons
Industry
Financing
Details
Praxis (Drug Discovery) Competitors (8)
One of Praxis (Drug Discovery)’s 8 competitors is SAGE Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| SAGE Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Stoke Therapeutics | Formerly VC-backed | Bedford, MA | ||||
| Xenon Pharmaceuticals | Formerly VC-backed | Burnaby, Canada | ||||
| Neurocrine Biosciences | Formerly VC-backed | San Diego, CA | ||||
| Aquinnah | Venture Capital-Backed | Cambridge, MA |
Praxis (Drug Discovery) Patents
Praxis (Drug Discovery) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023260468-A1 | Treatment of neurological disorders | Pending | 26-Apr-2022 | ||
| AU-2023260333-A1 | Treatment of neurological disorders | Pending | 26-Apr-2022 | ||
| US-20250041284-A1 | Treatment of neurological disorders | Pending | 26-Apr-2022 | ||
| US-20250049790-A1 | Treatment of neurological disorders | Pending | 26-Apr-2022 | ||
| AU-2023259123-A1 | Kcnt1 inhibitors comprising a pyrazole core and methods of use | Pending | 25-Apr-2022 | C07D401/14 |
Praxis (Drug Discovery) Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Praxis (Drug Discovery) ESG
Risk Overview
Risk Rating
Updated October, 01, 2023
34.63 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 15,842
Rank
Percentile
Pharmaceuticals
Industry
of 898
Rank
Percentile
Pharmaceuticals
Subindustry
of 428
Rank
Percentile
Praxis (Drug Discovery) FAQs
-
When was Praxis (Drug Discovery) founded?
Praxis (Drug Discovery) was founded in 2015.
-
Where is Praxis (Drug Discovery) headquartered?
Praxis (Drug Discovery) is headquartered in Boston, MA.
-
What is the size of Praxis (Drug Discovery)?
Praxis (Drug Discovery) has 82 total employees.
-
What industry is Praxis (Drug Discovery) in?
Praxis (Drug Discovery)’s primary industry is Drug Discovery.
-
Is Praxis (Drug Discovery) a private or public company?
Praxis (Drug Discovery) is a Public company.
-
What is Praxis (Drug Discovery)’s stock symbol?
The ticker symbol for Praxis (Drug Discovery) is PRAX.
-
What is the current stock price of Praxis (Drug Discovery)?
As of 14-Feb-2025 the stock price of Praxis (Drug Discovery) is $90.77.
-
What is the current market cap of Praxis (Drug Discovery)?
The current market capitalization of Praxis (Drug Discovery) is $1.69B.
-
What is Praxis (Drug Discovery)’s current revenue?
The trailing twelve month revenue for Praxis (Drug Discovery) is $1.6M.
-
Who are Praxis (Drug Discovery)’s competitors?
SAGE Therapeutics, Stoke Therapeutics, Xenon Pharmaceuticals, Neurocrine Biosciences, and Aquinnah are some of the 8 competitors of Praxis (Drug Discovery).
-
What is Praxis (Drug Discovery)’s annual earnings per share (EPS)?
Praxis (Drug Discovery)’s EPS for 12 months was -$9.17.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
